Navigation Links
As Risperdal Lawsuits Move Forward, Wright & Schulte LLC Learns of Bid to Keep Clinical Studies Sealed in Pennsylvania Risperdal Litigation
Date:12/11/2013

(PRWEB) December 11, 2013

Wright & Schulte LLC has learned that Johnson & Johnson has filed a motion in Risperdal lawsuits pending in Pennsylvania state court to keep sealed certain clinical studies pertaining to the antipsychotic drug. According to court documents filed in the Philadelphia Court of Common Pleas, the studies were originally sealed in 2011. In its November 26th motion, Johnson & Johnson urged the Court to allow the studies to stay sealed, as they were intended to be used by researchers and regulators, not the general public. (In Re: Risperdal Litigation, Case ID. 100300296)

The firm indicates that court records show more than 200 Risperdal lawsuits are pending in Pennsylvania, dozens of which were filed on behalf of alleged victims of gynecomastia, or male breast growth. Plaintiffs in these Risperdal gynecomastia lawsuits allege the use of the drug caused them to develop breasts so large that they have had to undergo liposuction or mastectomies to remove excess breast tissue. Even after undergoing breast reduction surgery, affected patients allegedly suffered psychological and emotional distress due to the development of gynecomastia. The complaints also accuse Johnson & Johnson of concealing the risk of male breast growth from patients and the medical community.

For more information on Risperdal lawsuits visit our website to stay connected to all the latest news.

Wright & Schulte LLC has also learned from a Bloomberg.com report of October 2012, Johnson & Johnson reached undisclosed settlements in five Risperdal gynecomastia lawsuits filed in the Pennsylvania litigation just before the cases went to trial. However, dozens of such claims remain unresolved. According to a motion filed on November 5th, plaintiffs in 77 other Risperdal gynecomastia lawsuits have asked the Court to enforce a settlement in their claims that Johnson & Johnson allegedly agreed to last January.
[Bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 10, 2012]

On November 4th, the U.S. Department of Justice reported that Johnson & Johnson had agreed to pay $2.2 billion to settle criminal and civil charges involving the off-label marketing of Risperdal and other drugs. The accord was one of the largest health care fraud settlements in U.S. history, the DOJ said. Among other things, federal prosecutors had charged that Risperdal was improperly marketed for use in children before being approved by the U.S. Food & Drug Administration for such purposes. They also alleged that the company concealed the risk of male breast growth.
[justice.gov/opa/pr/2013/November/13-ag-1170.html?source=email_rt_mc_body&app=n]

Victims of gynecomastia (male breast growth) allegedly associated with the use of Risperdal may be eligible to file their own Risperdal lawsuit. To learn more, or to arrange for a free legal consultation with an attorney at Wright & Schulte LLC, please visit yourlegalhelp.com.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
"A Leading Defective Drug Law Firm"
1-800-399-0795
http://www.yourlegalhelp.com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11413623.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
2. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
3. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
4. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
7. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
8. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
9. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2020)... ... January 23, 2020 , ... FEI Behavioral ... that improve workforce resilience, is presenting at the NATSAP 2020 Conference. , NATSAP, ... resource for organizations that devote themselves to society’s need for the effective care ...
(Date:1/23/2020)... ... January 23, 2020 , ... Today, The Fenway Institute ... the Trump Administration dramatically expanded upon discriminatory, anti-LGBT policies implemented in 2017 and ... and around the world. , “During Donald Trump’s third year as president, we ...
(Date:1/23/2020)... ... 23, 2020 , ... The Incentive Research Foundation is pleased ... Representing all segments of the incentives, rewards, and recognition industry, the IRF Board ... providing education highlighting the power of incentive and motivational programs. The Board recently ...
(Date:1/22/2020)... ... January 22, 2020 , ... ... management services, integrated practice management, and patient engagement solutions launched its new ... Health Record for Indian healthcare market at HITCON 2020 , held ...
(Date:1/22/2020)... California (PRWEB) , ... January 22, 2020 , ... ... like gastric sleeve and gastric lap band can be for reducing food intake, ... But Dr. Almanza also understands that while bariatric surgery may be a great ...
Breaking Medicine News(10 mins):
(Date:1/10/2020)... Vt. (PRWEB) , ... January 10, 2020 , ... By mid-January, many people’s New Year’s ... offering a “New Year, New Life” Eight Night Wellness Retreat for the 2020 season. , ... 2020 dates to include an extra week in May and the first weekend of October. ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... Institute of Silicon Valley, has this week announced the latest medical breakthrough for ... Molybdenum-Rhenium rod in a patient. , The newly FDA cleared MiRus Europa™ Pedicle ...
(Date:1/7/2020)... ... January 07, 2020 , ... Ironsphere, a ... providers, announced today it has been selected by MetLife Stadium for Privileged Access ... “As part of our ongoing commitment to maintain the highest of security policies, ...
Breaking Medicine Technology: